Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD
Advertisement
Articles by Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD
Advertisement
Latest Updated Articles
JNJ-4496 Prevents Antigen Escape, May Work as Salvage Therapy in R/R LBCLPublished: June 25th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Two-Fraction SBRT Shows Acceptable Toxicity in Prostate Cancer Population
2
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
3
How Does SC Mosunetuzumab Compare With Other Frontline MZL Therapies?
4
Managing Safety and Adverse Events in Practice
5
